Skip to main content
SpringerLink
Log in

Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The plasma concentrations and renal clearance values of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) were determined in 11 adult cancer patients maintained on a long term oral morphine dosage (10 to 100mg every 4h). Concentrations in plasma and urine were determined by a specific high performance liquid chromatography assay. In this group of patients, whose creatinine clearance values ranged from 52 to 180 ml/min (3.12 to 10.8 L/h), average steady-state plasma concentrations of morphine, M3G and M6G were related (p < 0.01) to the morphine dose per kilogram of bodyweight. The mean total urinary recovery as morphine, M3G and M6G was 74.6 ± 26.5% of the dose. Renal clearance values for M3G and M6G were closely related (r2 = 0.80; p < 0.0005). It was not possible to detect a relationship between the renal clearance of morphine, M3G and M6G, and that of creatinine. The renal tubular handling of all 3 compounds showed wide interindividual variation, and there was evidence of either net renal tubular secretion or reabsorption. There was no apparent relationship between plasma morphine and M6G concentrations and pain relief.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abbott FV, Palmour EM. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sciences 43: 1685–1695, 1988

    Article  PubMed  CAS  Google Scholar 

  • Bodd E, Jacobsen D, Lund E, Ripel Å, Mørland J, et al. Morphinc-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Human and Experimental Toxicology 9: 317–321, 1990

    Article  PubMed  CAS  Google Scholar 

  • Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sciences 48: 2165–2171, 1991

    Article  PubMed  CAS  Google Scholar 

  • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41, 1976

    Article  PubMed  CAS  Google Scholar 

  • Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Therapeutic Drug Monitoring 13: 1–23, 1991

    Article  PubMed  CAS  Google Scholar 

  • Hasselström J, Berg U, Löfgren A, Säwe J. Long lasting respiratory depression induced by morphine-6-glucuronide. British Journal of Clinical Pharmacology 27: 515–518, 1989

    Article  PubMed  Google Scholar 

  • Inturrisi CE. Effects of other drugs and pathologic states on opioid disposition and response. Advances in Pain Research and Therapy 14: 171–180, 1990

    Google Scholar 

  • Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 27: 117–126, 1986

    Article  PubMed  CAS  Google Scholar 

  • May DG, Fujimoto JM, Inturrisi CE. The tubular transport and metabolism of morphine-N-methyl-C14 by the chicken kidney. Journal of Pharmacology and Experimental Therapeutics 157: 626–635, 1967

    PubMed  CAS  Google Scholar 

  • McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, et al. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clinical Pharmacology and Therapeutics 48: 236–244, 1990

    Article  PubMed  CAS  Google Scholar 

  • Milne RW, Nation RL, Reynolds GD, Somogyi AA, van Crugten JT. High-performance liquid Chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. Journal of Chromatography 565: 457–464, 1991

    Article  PubMed  CAS  Google Scholar 

  • Milne RW, Nation RL, Somogyi AA, Bochner F, Griggs W. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. British Journal of Clinical Pharmacology 34: 53–59, 1992

    Article  PubMed  CAS  Google Scholar 

  • Muirhead M, Bochner F, Somogyi A. Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption. Journal of Pharmacology and Experimental Therapeutics 244: 734–739, 1988

    PubMed  CAS  Google Scholar 

  • Neumann PB, Henriksén H, Grosman N, Christensen CB. Plasma morphine concentrations during chronic oral administration in patients with cancer pain. Pain 13: 247–252, 1982

    Article  PubMed  CAS  Google Scholar 

  • Olsen GD. Morphine binding to human plasma proteins. Clinical Pharmacology and Therapeutics 17: 31–35, 1975

    PubMed  CAS  Google Scholar 

  • Olsen GD, Bennett WM, Porter GA. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clinical Pharmacology and Therapeutics 17, 677–684, 1975

    PubMed  CAS  Google Scholar 

  • Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. British Medical Journal 292: 1548–1549, 1986

    Article  PubMed  CAS  Google Scholar 

  • Osborne RJ, Joel SP, Trew D, Slevin ML. The analgesic activity of morphine-6-glucuronide. Lancet 1: 828, 1988

    Article  PubMed  CAS  Google Scholar 

  • Osborne RJ, Joel SP, Trew D, Slevin ML. Morphine and metabolite behaviour after different routes of administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clinical Pharmacology and Therapeutics 47: 12–19, 1990

    Article  PubMed  CAS  Google Scholar 

  • Osborne R, Thompson P, Joel S, Trew D, Patel N, et al. The analgesic activity of morphine-6-glucuronide. British Journal of Clinical Pharmacology 34: 130–138, 1992

    Article  PubMed  CAS  Google Scholar 

  • Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist. Life Sciences 41: 2845–2849, 1987

    Article  PubMed  CAS  Google Scholar 

  • Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. Journal of Pharmacology and Experimental Therapeutics 251: 477–483, 1989

    PubMed  CAS  Google Scholar 

  • Peterson GM. Randall CTC, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. European Journal of Clinical Pharmacology 38: 121–124, 1990

    Article  PubMed  CAS  Google Scholar 

  • Poulain P, Hoskin PJ, Hanks GW. A-Omar O, Walker VA, et al. Relative bioavailability of controlled release morphine tablets (MST Continus) in cancer patients. British Journal of Anaesthesia 61: 569–574, 1988

    Article  PubMed  CAS  Google Scholar 

  • Säwe J. Morphine and its 3- and 6-glucuronides in plasma and urine during chronic oral administration in cancer patients. Advances in Pain Research and Therapy 8: 45–55, 1986

    Google Scholar 

  • Säwe J, Kager L, Svensson Eng J-O, Rane A. Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. British Journal of Clinical Pharmacology 19: 495–501, 1985

    Article  PubMed  Google Scholar 

  • Säwe J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses — no evidence for autoinduction or dose-dependence. British Journal of Clinical Pharmacology 16: 85–93, 1983

    Article  PubMed  Google Scholar 

  • Schali C, Roch-Ramel F. Transport and metabolism of [3H]morphine in isolated, nonperfused proximal tubular segments of the rabbit kidney. Journal of Pharmacology and Experimental Therapeutics 223: 811–815, 1982

    PubMed  CAS  Google Scholar 

  • Shimomura K, Kamata O, Ueki S, Ida S, Yoshimura H, et al. Analgesic effect of morphine glucuronides. Tohoku Journal of Experimental Medicine 105: 45–52, 1971

    Article  PubMed  CAS  Google Scholar 

  • Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide — a potent antagonist of morphine analgesia. Life Sciences 47: 579–585, 1990

    Article  PubMed  CAS  Google Scholar 

  • Takeda F. WHO cancer pain relief programme. In Bond et al. (Eds) Proceedings of the VIth World Congress on Pain, pp. 467–474, Elsevier, Amsterdam, 1991

    Google Scholar 

  • van Crugten JT, Sallustio BC, Nation RL, Somogyi AA. Renal tubular transport of morphine, morphine-6-glucuronide and morphine-3-glucuronide in the isolated perfused rat kidney. Drug Metabolism and Disposition 19: 1087–1092, 1991a

    PubMed  Google Scholar 

  • van Crugten JT, Somogyi AA, Nation RL. Kinetic-dynamic relationships of morphine (M) and morphine-6-glucuronide (M6G) in the rat. Clinical and Experimental Pharmacology and Physiology (Suppl. 18): 63, 1991b

    Google Scholar 

  • Watt JA, Cramond T, Smith MT. Morphine-6-glucuronide: analgesic effects antagonized by morphine-3-glucuronide. Clinical and Experimental Pharmacology and Physiology (Suppl. 17): 83, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Pharmacology, University of Adelaide, Australia

    Andrew A. Somogyi, Roger L. Nation, Charles Olweny, Panagiotis Tsirgiotis, Jacoba van Crugten, Robert W. Milne, James F. Cleary, Catherine Danz & Felix Bochner

  2. School of Pharmacy, University of South Australia, Australia

    Andrew A. Somogyi, Roger L. Nation, Charles Olweny, Panagiotis Tsirgiotis, Jacoba van Crugten, Robert W. Milne, James F. Cleary, Catherine Danz & Felix Bochner

  3. Departments of Clinical Pharmacology and Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia

    Andrew A. Somogyi, Roger L. Nation, Charles Olweny, Panagiotis Tsirgiotis, Jacoba van Crugten, Robert W. Milne, James F. Cleary, Catherine Danz & Felix Bochner

Authors
  1. Andrew A. Somogyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger L. Nation
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles Olweny
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Panagiotis Tsirgiotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacoba van Crugten
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert W. Milne
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James F. Cleary
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Catherine Danz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Felix Bochner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Somogyi, A.A., Nation, R.L., Olweny, C. et al. Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine. Clin. Pharmacokinet. 24, 413–420 (1993). https://doi.org/10.2165/00003088-199324050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199324050-00005

Keywords

Search

Navigation